VANCOUVER, British Columbia — A phase 1b/2 clinical trial of AU-011, a light-activated, vision-sparing, tumor cell selective therapy for patients with choroidal melanoma, showed the treatment was safe and resulted in no vision loss for up to 12 months, according to a speaker here.
“AU-011 appears to be safe in early trials and is well tolerated. There is inflammation. It seems to start within the tumor and then enlarge, and is probably related to tumor necrosis and may be beneficial and is manageable. Vision in these patients appears (Read more...)